NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Forecast, Price & News

$5.95

+0.04 (+0.68%)

(As of 06/9/2023 ET)

Compare

Today's Range: $5.86
▼
$6.48
50-Day Range: $5.65
▼
$9.93
52-Week Range: $2.00
▼
$10.30

Volume: 117,181 shs
Average Volume: 152,883 shs
Market Capitalization: $107.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Achieve Life Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 213.7% Upside
$18.67 Price Target
Short Interest: Bearish
3.51% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.21
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$27,500 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.59) to ($1.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

472nd out of 987 stocks

Diagnostic Substances Industry

7th out of 15 stocks

3.5

Analyst's Opinion

Consensus Rating
Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.67, Achieve Life Sciences has a forecasted upside of 213.7% from its current price of $5.95.
Amount of Analyst Coverage
Achieve Life Sciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.51% of the outstanding shares of Achieve Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Achieve Life Sciences has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in Achieve Life Sciences has recently increased by 11.17%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Achieve Life Sciences does not currently pay a dividend.
Dividend Growth
Achieve Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACHV.

2.9

News and Social Media Coverage

News Sentiment
Achieve Life Sciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.
Search Interest
22 people have searched for ACHV on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.
MarketBeat Follows
7 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achieve Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Achieve Life Sciences is held by insiders.
Percentage Held by Institutions
Only 21.11% of the stock of Achieve Life Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.59) to ($1.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Achieve Life Sciences is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Achieve Life Sciences is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Achieve Life Sciences has a P/B Ratio of 12.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Stock News Headlines

June 6, 2023 | finance.yahoo.com

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

June 3, 2023 | americanbankingnews.com

John Bencich Buys 5,000 Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) Stock

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

June 3, 2023 | americanbankingnews.com

Lake Street Capital Cuts Achieve Life Sciences (NASDAQ:ACHV) Price Target to $19.00

June 1, 2023 | msn.com

Lake Street Maintains Achieve Life Sciences (ACHV) Buy Recommendation

May 31, 2023 | bizjournals.com

Achieve Life Sciences raises $16.5M in pursuit of anti-smoking drug

May 31, 2023 | americanbankingnews.com

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Short Interest Update

May 25, 2023 | msn.com

Achieve Life Sciences stock down on pricing $16.5M stock offering

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

May 25, 2023 | finance.yahoo.com

ACHV: ORCA-3 Topline

May 25, 2023 | finance.yahoo.com

Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

May 24, 2023 | finance.yahoo.com

Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) Shift From Loss To Profit

May 23, 2023 | markets.businessinsider.com

Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Achieve Life Sciences (ACHV)

May 23, 2023 | finance.yahoo.com

Can't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial

May 23, 2023 | finance.yahoo.com

Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

May 17, 2023 | finance.yahoo.com

Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank

May 16, 2023 | americanbankingnews.com

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Expected to Earn Q2 2023 Earnings of ($0.40) Per Share

May 13, 2023 | americanbankingnews.com

Achieve Life Sciences (NASDAQ:ACHV) and Virax Biolabs Group (NASDAQ:VRAX) Head to Head Survey

May 13, 2023 | americanbankingnews.com

Maxim Group Raises Achieve Life Sciences (NASDAQ:ACHV) Price Target to $20.00

May 11, 2023 | seekingalpha.com

Achieve Life Sciences GAAP EPS of -$0.50 beats by $0.19

May 11, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Achieve Life Sciences (ACHV), NGM Biopharmaceuticals (NGM) and Cutera (CUTR)

May 11, 2023 | americanbankingnews.com

Achieve Life Sciences (NASDAQ:ACHV) PT Raised to $20.00 at Maxim Group

May 10, 2023 | finance.yahoo.com

ACHV: First Quarter Results

May 10, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Achieve Life Sciences (ACHV) and uniQure (QURE)

May 10, 2023 | finance.yahoo.com

Q1 2023 Achieve Life Sciences Inc Earnings Call

May 9, 2023 | finance.yahoo.com

Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update

May 8, 2023 | investing.com

Achieve Life Sciences (ACHV) Earnings Dates & Reports

See More Headlines

ACHV Price History

30 days | 90 days | 365 days | Advanced Chart

ACHV Company Calendar

Last Earnings: 3/16/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ACHV
CUSIP: 68230A10
CIK: 949858
Web: achievelifesciences.com
Phone: (604) 210-2217
Fax: 425-686-1600
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.67
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $17.00
Forecasted Upside/Downside: +213.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -762.66%
Return on Assets: -161.40%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 0.90
Quick Ratio: 0.90

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.46 per share
Price / Book: 12.93

Miscellaneous

Outstanding Shares: 18,040,000
Free Float: 17,680,000
Market Cap: $107.34 million
Optionable: Not Optionable
Beta: 1.56

Key Executives

John A. Bencich
Director, Chief Executive & Financial Officer

Cindy A. Jacobs
President, Chief Medical Officer & Director

Anthony John Clarke
Chief Scientific Officer

Jaime Xinos
Executive Vice President-Commercial

Jerry Wan
Principal Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACHV Stock - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.
What is Achieve Life Sciences' stock price forecast for 2023?: 2 brokerages have issued 12-month target prices for Achieve Life Sciences' shares. Their ACHV share price forecasts range from $17.00 to $20.00. On average, they predict the company's share price to reach $18.67 in the next year. This suggests a possible upside of 213.7% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.
How have ACHV shares performed in 2023?: Achieve Life Sciences' stock was trading at $2.45 at the beginning of the year. Since then, ACHV shares have increased by 142.9% and is now trading at $5.95.
View the best growth stocks for 2023 here.
When is Achieve Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ACHV earnings forecast.
How were Achieve Life Sciences' earnings last quarter?: Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.07. During the same quarter in the previous year, the business earned ($0.76) EPS.
What ETF holds Achieve Life Sciences' stock ?: AdvisorShares Dorsey Wright Micro-Cap ETF holds 2,360 shares of ACHV stock, representing 0.34% of its portfolio.

When did Achieve Life Sciences' stock split?: Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Achieve Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).
What is Achieve Life Sciences' stock symbol?: Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."
Who are Achieve Life Sciences' major shareholders?: Achieve Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (1.00%), LPL Financial LLC (0.80%), Long Focus Capital Management LLC (0.78%), Perkins Capital Management Inc. (0.77%), Raymond James & Associates (0.58%) and Susquehanna International Group LLP (0.00%).
View institutional ownership trends.
How do I buy shares of Achieve Life Sciences?: Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Achieve Life Sciences' stock price today?: One share of ACHV stock can currently be purchased for approximately $5.95.
How much money does Achieve Life Sciences make?: Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $107.34 million. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($3.76) on an earnings per share basis.
How can I contact Achieve Life Sciences?: Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.

This page (NASDAQ:ACHV) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial